PanoramicaGraficoNotizieSchermataTrader

CLINUVEL PHARMACEUTICALS/  AU000000CUV3  /

Frankfurt
15/11/2024  16:57:35 Var. -0.0900 Volume Denaro21:58:39 Lettera21:58:39 Max Min
8.1150EUR -1.10% 800
Fatturato: 6,489		 -Quantità in denaro: - -Quantità in lettera: - 8.1150 8.0500
GlobeNewswire 18/06 Afamelanotide in fair-skinned Parkinson’s patients
GlobeNewswire 28/03 Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
GlobeNewswire 05/03 Malibu shines a light on CLINUVEL’s pioneering work in photomedicine
GlobeNewswire 08/11/2021 CLINUVEL Expands Pharmaceutical Portfolio
GlobeNewswire 24/03/2021 CLINUVEL expands DNA Repair Program
GlobeNewswire 27/10/2020 CLINUVEL to Trial Innovative Drug in Stroke
GlobeNewswire 15/09/2020 First patient dosed in SCENESSE® DNA Repair Program
GlobeNewswire 10/09/2020 CLINUVEL progresses innovative DNA Repair Program
GlobeNewswire 31/08/2020 CLINUVEL Opens VALLAURIX R&D Centre In Singapore
GlobeNewswire 13/07/2020 PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
GlobeNewswire 23/04/2020 SCENESSE® to be Prescribed in China
GlobeNewswire 16/04/2020 Innovative drug launched for rare, isolating, “light intolerance” disorder
GlobeNewswire 09/10/2019 FDA Approves SCENESSE® For Genetic Disorder
GlobeNewswire 03/06/2019 US FDA Review for SCENESSE® Extended by Three Months
GlobeNewswire 10/01/2019 US FDA sets PDUFA date for SCENESSE®
GlobeNewswire 19/12/2018 Phase II study: SCENESSE® in combination with narrowband ultraviolet B (NB-UVB) achieves repigmentat...
GlobeNewswire 29/08/2018 CLINUVEL delivers second positive financial result
GlobeNewswire 25/06/2018 FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
GlobeNewswire 20/02/2018 CLINUVEL unveils new global positioning
GlobeNewswire 22/01/2018 Nasdaq Welcomes Cielo S.A. to the Nasdaq International Designation
GlobeNewswire 22/01/2018 Nasdaq Welcomes Cielo S.A. to the Nasdaq International Designation
GlobeNewswire 12/04/2017 CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
GlobeNewswire 01/06/2016 Nasdaq Welcomes Additional Companies to the Nasdaq International Designation